Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
EAST HANOVER, N.J., Sept. 19, 2021 /PRNewswire/ — Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali® (ribociclib) in combination with letrozole compared to placebo plus letrozole in postmenopausal…
Comments Off on Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer